These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 37575726)

  • 21. Increasing Levels of Serum Anti-Spike S1-RBD IgG after 120 Days of the Pfizer-BioNTech-mRNA Second Dose Vaccination.
    Abdul-Wahab Kadhum A; Rushdi Abdullah A; Mujahid A
    Arch Razi Inst; 2023 Jun; 78(3):1071-1075. PubMed ID: 38028836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G Levels After the Pfizer-BioNTech Booster Dose for Coronavirus Disease 2019 (COVID-19) Vaccination During the Second Trimester of Pregnancy.
    Kugelman N; Nahshon C; Shaked-Mishan P; Kleifeld S; Cohen N; Sher ML; Zahran H; Barsha H; Assaf W; Shalabna E; Stein N; Lavie O; Kedar R; Riskin-Mashiah S
    Obstet Gynecol; 2022 Aug; 140(2):187-193. PubMed ID: 35852268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Waning Immunity after the BNT162b2 Vaccine in Israel.
    Goldberg Y; Mandel M; Bar-On YM; Bodenheimer O; Freedman L; Haas EJ; Milo R; Alroy-Preis S; Ash N; Huppert A
    N Engl J Med; 2021 Dec; 385(24):e85. PubMed ID: 34706170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of action of mRNA-based vaccines.
    Iavarone C; O'hagan DT; Yu D; Delahaye NF; Ulmer JB
    Expert Rev Vaccines; 2017 Sep; 16(9):871-881. PubMed ID: 28701102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection.
    Callow KA
    J Hyg (Lond); 1985 Aug; 95(1):173-89. PubMed ID: 2991366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review.
    Notarte KI; Guerrero-Arguero I; Velasco JV; Ver AT; Santos de Oliveira MH; Catahay JA; Khan MSR; Pastrana A; Juszczyk G; Torrelles JB; Lippi G; Martinez-Sobrido L; Henry BM
    J Med Virol; 2022 Jul; 94(7):2939-2961. PubMed ID: 35229324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody Response against Severe Acute Respiratory Syndrome Coronavirus 2 Messenger Ribonucleic Acid Vaccines in Infected Individuals: A Systematic Review.
    Roslan M; Mohd Nisfu FR; Arzmi MH; Abdul Wahab R; Zainuddin N
    Malays J Med Sci; 2023 Aug; 30(4):8-24. PubMed ID: 37655145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2.
    Jamous YF; Alhomoud DA
    Cureus; 2023 Sep; 15(9):e45602. PubMed ID: 37868494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic.
    Yap C; Ali A; Prabhakar A; Prabhakar A; Pal A; Lim YY; Kakodkar P
    Ther Adv Vaccines Immunother; 2021; 9():25151355211059791. PubMed ID: 34870090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insights into COVID-19 vaccines development: Translation from benchside to bedside.
    Houssein M; Al Hossainy AEA; Al Soussi J; El Batch J; El-Samadi L; El Imam S; Fakih R; Dakdouk H; Khalil M
    Health Sci Rev (Oxf); 2022 Sep; 4():100040. PubMed ID: 35856085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines.
    Uddin MN; Roni MA
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effect of Third Dose of Pfizer/BioNTech and Moderna COVID-19 mRNA Vaccines on IgG Antibody Titers.
    Khuc TA; Pequeno G; Betancourt-Garcia M; Casciato AM; Gomez-Martinez M; Arroyo CD; Pope BD; Narmala S; Rao S
    Cureus; 2023 Jul; 15(7):e41696. PubMed ID: 37575726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.